Delivery strategies to enhance oral vaccination against enteric infections

Advanced Drug Delivery Reviews

Volumn 91, Issue , 2015, Pages 52-69

  Davitt, Christopher J H ^a   Lavelle, Ed C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adjuvant; Delivery system; Gastrointestinal; Mucosal; Nanoparticle; Oral; Vaccine

Indexed keywords

ANTIGENS; DISEASES; NANOPARTICLES; SALMONELLA;

ADJUVANT; DELIVERY SYSTEMS; GASTROINTESTINAL; MUCOSAL; ORAL;

VACCINES;

ALGINIC ACID; AS01; BETA GLUCAN; CAF01; CARBOXYMETHYLETHYLCELLULOSE; CHENODEOXYCHOLIC ACID; CHITOSAN; CHOLERA VACCINE; DEOXYCHOLIC ACID; DNA VACCINE; ENTEROTOXIN; EUDRAGIT; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INJECTABLE POLIO VACCINE; LIPOSOME; MUCORICE; NANOPARTICLE; ORAL POLIOMYELITIS VACCINE; POLYGLACTIN; POLYLACTIC ACID; ROTAVIRUS VACCINE; SECRETORY IMMUNOGLOBULIN; SYNTHETIC PEPTIDE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; BIODEGRADABILITY; BURKHOLDERIA PSEUDOMALLEI; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHOLERA; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; EMULSION; ENTEROTOXOGENIC ESCHERICHIA COLI; ENTEROTOXOGENIC ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FOLLICULAR DENDRITIC CELL; GASTROINTESTINAL TRACT; GLUCAN PARTICLE; GREENHOUSE EFFECT; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INTESTINE; INTESTINE INFECTION; LUNG PARENCHYMA; MELIOIDOSIS; MEMBRANE VESICLE; MESENTERY LYMPH NODE; MICELLE; MONONUCLEAR PHAGOCYTE; MUCOADHESION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PHYSICAL CHEMISTRY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; ROTAVIRUS; SALMONELLA ENTERICA SEROVAR TYPHI; SINGLE DRUG DOSE; STROMA CELL; TH1 CELL; TH17 CELL; VACCINATION; VIBRIO CHOLERAE; VIRUS LIKE AGENT; ANIMAL; GASTROINTESTINAL DISEASES; IMMUNOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; DIARRHEA; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL DISEASES; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; VACCINATION; VACCINES;

EID: 84940953399     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.007     Document Type: Review

References (259)

1. Cheng A.C., McDonald J.R., Thielman N.M. Infectious diarrhea in developed and developing countries. J. Clin. Gastroenterol. 2005, 39:757-773.
2. Liu L., Johnson H.L., Cousens S., Perin J., Scott S., Lawn J.E., Rudan I., Campbell H., Cibulskis R., Li M., Mathers C., Black R.E. W.H.O. Child Health Epidemiology Reference Group of, Unicef, Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379:2151-2161.
3. Petri W.A., Miller M., Binder H.J., Levine M.M., Dillingham R., Guerrant R.L. Enteric infections, diarrhea, and their impact on function and development. J. Clin. Invest. 2008, 118:1277-1290.
4. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., Wu Y., Sow S.O., Sur D., Breiman R.F., Faruque A.S., Zaidi A.K., Saha D., Alonso P.L., Tamboura B., Sanogo D., Onwuchekwa U., Manna B., Ramamurthy T., Kanungo S., Ochieng J.B., Omore R., Oundo J.O., Hossain A., Das S.K., Ahmed S., Qureshi S., Quadri F., Adegbola R.A., Antonio M., Hossain M.J., Akinsola A., Mandomando I., Nhampossa T., Acacio S., Biswas K., O'Reilly C.E., Mintz E.D., Berkeley L.Y., Muhsen K., Sommerfelt H., Robins-Browne R.M., Levine M.M. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382:209-222.
5. Svennerholm A.M. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J. Med. Res. 2011, 133:188-196.
6. Tobias J., Svennerholm A.M. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates. Appl. Microbiol. Biotechnol. 2012, 93:2291-2300.
7. Huq A., Sack R.B., Nizam A., Longini I.M., Nair G.B., Ali A., Morris J.G., Khan M.N., Siddique A.K., Yunus M., Albert M.J., Sack D.A., Colwell R.R. Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh. Appl. Environ. Microbiol. 2005, 71:4645-4654.
8. Health Cluster Bulletin #15, Pan American Health Organization http://new.paho.org/hai/index.php?lang5en.
9. Carter N.J., Curran M.P. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71:1591-1622.
10. Anh D.D., Lopez A.L., Thiem V.D., Grahek S.L., Duong T.N., Park J.K., Kwon H.J., Favorov M., Hien N.T., Clemens J.D. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl. Trop. Dis. 2011, 5:e1006.
11. Date K.A., Vicari A., Hyde T.B., Mintz E., Danovaro-Holliday M.C., Henry A., Tappero J.W., Roels T.H., Abrams J., Burkholder B.T., Ruiz-Matus C., Andrus J., Dietz V. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011. Emerg. Infect. Dis. 2011, 17:2105-2112.
12. Mantis N.J., Morici L.A., Roy C.J. Mucosal vaccines for biodefense. Curr. Top. Microbiol. Immunol. 2012, 354:181-195.
13. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc. (Baylor Univ. Med. Cent.) 2005, 18:21-25.
14. Murphy K.P., Travers P., Walport M., Janeway C. Janeway's immunobiology 2008, Garland Science, New York. 7th ed.
15. Modlin J., Wenger J. Achieving and maintaining polio eradication-new strategies. N. Engl. J. Med. 2014, 371:1476-1479.
16. Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew O.M., Pallansch M.A., Orenstein W.A., Hinman A.R. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 1992, 14:568-579.
17. Levine M.M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010, 8:129.
18. Walker R.I. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 2005, 23:3369-3385.
19. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 2012, 12:592-605.
20. Levine M.M., Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998, 351:1375-1376.
21. Yuki Y., Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev. Vaccines 2009, 8:1083-1097.
22. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., Spencer A.J., Honeycutt J.D., Wyllie D.H., Gilbert S.C., Bregu M., Hill A.V. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2010, 2:19ra12.
23. Pastor M., Esquisabel A., Talavera A., Ano G., Fernandez S., Cedre B., Infante J.F., Callico A., Pedraz J.L. An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int. J. Pharm. 2013, 448:247-258.
24. Neutra M.R., Pringault E., Kraehenbuhl J.P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 1996, 14:275-300.
25. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 2005, 11:S45-S53.
26. Pasetti M.F., Simon J.K., Sztein M.B., Levine M.M. Immunology of gut mucosal vaccines. Immunol. Rev. 2011, 239:125-148.
27. John J., Giri S., Karthikeyan A.S., Iturriza-Gomara M., Muliyil J., Abraham A., Grassly N.C., Kang G. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014, 384:1505-1512.
28. Holmgren J., Svennerholm A.M. Vaccines against mucosal infections. Curr. Opin. Immunol. 2012, 24:343-353.
29. Schenk M., Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract. Res. Clin. Gastroenterol. 2008, 22:391-409.
30. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1482-1487.
31. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
32. Corfield A.P., Carroll D., Myerscough N., Probert C.S. Mucins in the gastrointestinal tract in health and disease. Front. Biosci. 2001, 6:D1321-D1357.
33. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
34. Mowat A.M., Agace W.W. Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 2014, 14:667-685.
35. Lai S.K., Hida K., Shukair S., Wang Y.Y., Figueiredo A., Cone R., Hope T.J., Hanes J. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol. 2009, 83:11196-11200.
36. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6:148-158.
37. Ermund A., Schutte A., Johansson M.E., Gustafsson J.K., Hansson G.C. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305:G341-G347.
38. Kararli T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 1995, 16:351-380.
39. Sack D.A., Qadri F., Svennerholm A.M. Determinants of responses to oral vaccines in developing countries. Ann. Nestle Eng. 2008, 66:71-79.
40. Kaufman D.R., De Calisto J., Simmons N.L., Cruz A.N., Villablanca E.J., Mora J.R., Barouch D.H. Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity. J. Immunol. 2011, 187:1877-1883.
41. Valdez Y., Brown E.M., Finlay B.B. Influence of the microbiota on vaccine effectiveness. Trends Immunol. 2014, 35:526-537.
42. Niess J.H., Brand S., Gu X., Landsman L., Jung S., McCormick B.A., Vyas J.M., Boes M., Ploegh H.L., Fox J.G., Littman D.R., Reinecker H.C. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005, 307:254-258.
43. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., Granucci F., Kraehenbuhl J.P., Ricciardi-Castagnoli P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2:361-367.
44. Jang M.H., Kweon M.N., Iwatani K., Yamamoto M., Terahara K., Sasakawa C., Suzuki T., Nochi T., Yokota Y., Rennert P.D., Hiroi T., Tamagawa H., Iijima H., Kunisawa J., Yuki Y., Kiyono H. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6110-6115.
45. Jensen V.B., Harty J.T., Jones B.D. Interactions of the invasive pathogens Salmonella typhimurium, Listeria monocytogenes, and Shigella flexneri with M cells and murine Peyer's patches. Infect. Immun. 1998, 66:3758-3766.
46. McDole J.R., Wheeler L.W., McDonald K.G., Wang B., Konjufca V., Knoop K.A., Newberry R.D., Miller M.J. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 2012, 483:345-349.
47. Neutra M.R., Frey A., Kraehenbuhl J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996, 86:345-348.
48. Mabbott N.A., Donaldson D.S., Ohno H., Williams I.R., Mahajan A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013, 6:666-677.
49. Thejani D.D.L., Rajapaksa E. Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Curr. Immunol. Rev. 2010, 6:29-37.
50. Giannasca P.J., Giannasca K.T., Leichtner A.M., Neutra M.R. Human intestinal M cells display the sialyl Lewis A antigen. Infect. Immun. 1999, 67:946-953.
51. Craig S.W., Cebra J.J. Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit. J. Exp. Med. 1971, 134:188-200.
52. Shikina T., Hiroi T., Iwatani K., Jang M.H., Fukuyama S., Tamura M., Kubo T., Ishikawa H., Kiyono H. IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J. Immunol. 2004, 172:6259-6264.
53. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., Kadokura K., Tobe T., Fujimura Y., Kawano S., Yabashi A., Waguri S., Nakato G., Kimura S., Murakami T., Iimura M., Hamura K., Fukuoka S., Lowe A.W., Itoh K., Kiyono H., Ohno H. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
54. Kanaya T., Hase K., Takahashi D., Fukuda S., Hoshino K., Sasaki I., Hemmi H., Knoop K.A., Kumar N., Sato M., Katsuno T., Yokosuka O., Toyooka K., Nakai K., Sakamoto A., Kitahara Y., Jinnohara T., McSorley S.J., Kaisho T., Williams I.R., Ohno H. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat. Immunol. 2012, 13:729-736.
55. Lelouard H., Fallet M., de Bovis B., Meresse S., Gorvel J.P. Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology 2012, 142:592-601.e593.
56. Sierro F., Dubois B., Coste A., Kaiserlian D., Kraehenbuhl J.P., Sirard J.C. Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13722-13727.
57. Ebisawa M., Hase K., Takahashi D., Kitamura H., Knoop K.A., Williams I.R., Ohno H. CCR6hiCD11c(int) B cells promote M-cell differentiation in Peyer's patch. Int. Immunol. 2011, 23:261-269.
58. Kobayashi A., Donaldson D.S., Erridge C., Kanaya T., Williams I.R., Ohno H., Mahajan A., Mabbott N.A. The functional maturation of M cells is dramatically reduced in the Peyer's patches of aged mice. Mucosal Immunol. 2013, 6:1027-1037.
59. Westphal S., Lugering A., von Wedel J., von Eiff C., Maaser C., Spahn T., Heusipp G., Schmidt M.A., Herbst H., Williams I.R., Domschke W., Kucharzik T. Resistance of chemokine receptor 6-deficient mice to Yersinia enterocolitica infection: evidence of defective M-cell formation in vivo. Am. J. Pathol. 2008, 172:671-680.
60. Rand J.H., Wu X.X., Lin E.Y., Griffel A., Gialanella P., McKitrick J.C. Annexin A5 binds to lipopolysaccharide and reduces its endotoxin activity. mBio 2012, 3.
61. Kadaoui K.A., Corthesy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J. Immunol. 2007, 179:7751-7757.
62. Rey J., Garin N., Spertini F., Corthesy B. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. J. Immunol. 2004, 172:3026-3033.
63. Rochereau N., Drocourt D., Perouzel E., Pavot V., Redelinghuys P., Brown G.D., Tiraby G., Roblin X., Verrier B., Genin C., Corthesy B., Paul S. Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells. PLoS Biol. 2013, 11:e1001658.
64. Halle S., Bumann D., Herbrand H., Willer Y., Dahne S., Forster R., Pabst O. Solitary intestinal lymphoid tissue provides a productive port of entry for Salmonella enterica serovar Typhimurium. Infect. Immun. 2007, 75:1577-1585.
65. Martinoli C., Chiavelli A., Rescigno M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity 2007, 27:975-984.
66. Suzuki K., Meek B., Doi Y., Honjo T., Fagarasan S. Two distinctive pathways for recruitment of naive and primed IgM+ B cells to the gut lamina propria. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2482-2486.
67. Tsuji M., Suzuki K., Kitamura H., Maruya M., Kinoshita K., Ivanov I.I., Itoh K., Littman D.R., Fagarasan S. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 2008, 29:261-271.
68. King C., Tangye S.G., Mackay C.R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu. Rev. Immunol. 2008, 26:741-766.
69. Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004, 303:1662-1665.
70. Iwasaki A., Kelsall B.L. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 1999, 190:229-239.
71. Mora J.R., Iwata M., Eksteen B., Song S.Y., Junt T., Senman B., Otipoby K.L., Yokota A., Takeuchi H., Ricciardi-Castagnoli P., Rajewsky K., Adams D.H., von Andrian U.H. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006, 314:1157-1160.
72. Sato A., Hashiguchi M., Toda E., Iwasaki A., Hachimura S., Kaminogawa S. CD11b+ Peyer's patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells. J. Immunol. 2003, 171:3684-3690.
73. Ruane D.T., Lavelle E.C. The role of CD103(+) dendritic cells in the intestinal mucosal immune system. Front. Immunol. 2011, 2:25.
74. Schulz O., Jaensson E., Persson E.K., Liu X., Worbs T., Agace W.W., Pabst O. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J. Exp. Med. 2009, 206:3101-3114.
75. Lin Y., Slight S.R., Khader S.A. Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. 2010, 32:79-90.
76. Cha H.R., Ko H.J., Kim E.D., Chang S.Y., Seo S.U., Cuburu N., Ryu S., Kim S., Kweon M.N. Mucosa-associated epithelial chemokine/CCL28 expression in the uterus attracts CCR10+ IgA plasma cells following mucosal vaccination via estrogen control. J. Immunol. 2011, 187:3044-3052.
77. Scott C.L., Aumeunier A.M., Mowat A.M. Intestinal CD103+ dendritic cells: master regulators of tolerance?. Trends Immunol. 2011, 32:412-419.
78. Semmrich M., Plantinga M., Svensson-Frej M., Uronen-Hansson H., Gustafsson T., Mowat A.M., Yrlid U., Lambrecht B.N., Agace W.W. Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responses. Mucosal Immunol. 2012, 5:150-160.
79. Ruane D., Brane L., Reis B.S., Cheong C., Poles J., Do Y., Zhu H., Velinzon K., Choi J.H., Studt N., Mayer L., Lavelle E.C., Steinman R.M., Mucida D., Mehandru S. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J. Exp. Med. 2013, 210:1871-1888.
80. del Rio M.L., Bernhardt G., Rodriguez-Barbosa J.I., Forster R. Development and functional specialization of CD103+ dendritic cells. Immunol. Rev. 2010, 234:268-281.
81. Mora J.R., von Andrian U.H. Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 2008, 1:96-109.
82. Feng N., Jaimes M.C., Lazarus N.H., Monak D., Zhang C., Butcher E.C., Greenberg H.B. Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+ plasmablast recruitment to the intestinal lamina propria after rotavirus infection. J. Immunol. 2006, 176:5749-5759.
83. Sheridan B.S., Lefrancois L. Regional and mucosal memory T cells. Nat. Immunol. 2011, 12:485-491.
84. Mora J.R., von Andrian U.H. Role of retinoic acid in the imprinting of gut-homing IgA-secreting cells. Semin. Immunol. 2009, 21:28-35.
85. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 2004, 4:699-710.
86. Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 2010, 39:303-355.
87. Bevan M.J. Memory T cells as an occupying force. Eur. J. Immunol. 2011, 41:1192-1195.
88. Blaschitz C., Raffatellu M. Th17 cytokines and the gut mucosal barrier. J. Clin. Immunol. 2010, 30:196-203.
89. Feng T., Elson C.O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol. 2011, 4:15-21.
90. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 2008, 1:11-22.
91. Kaetzel C.S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 2005, 206:83-99.
92. Kilian M., Reinholdt J., Lomholt H., Poulsen K., Frandsen E.V. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 1996, 104:321-338.
93. Mantis N.J., Forbes S.J. Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol. Invest. 2010, 39:383-406.
94. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
95. Pabst O. New concepts in the generation and functions of IgA. Nat. Rev. Immunol. 2012, 12:821-832.
96. Palm N.W., de Zoete M.R., Cullen T.W., Barry N.A., Stefanowski J., Hao L., Degnan P.H., Hu J., Peter I., Zhang W., Ruggiero E., Cho J.H., Goodman A.L., Flavell R.A. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014, 158:1000-1010.
97. Harris N.L., Spoerri I., Schopfer J.F., Nembrini C., Merky P., Massacand J., Urban J.F., Lamarre A., Burki K., Odermatt B., Zinkernagel R.M., Macpherson A.J. Mechanisms of neonatal mucosal antibody protection. J. Immunol. 2006, 177:6256-6262.
98. Tokuhara D., Yuki Y., Nochi T., Kodama T., Mejima M., Kurokawa S., Takahashi Y., Nanno M., Nakanishi U., Takaiwa F., Honda T., Kiyono H. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8794-8799.
99. Sanchez J., Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr. Opin. Immunol. 2005, 17:388-398.
100. Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 2001, 14:430-445.
101. Holmgren J., Bourgeois L., Carlin N., Clements J., Gustafsson B., Lundgren A., Nygren E., Tobias J., Walker R., Svennerholm A.M. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 2013, 31:2457-2464.
102. Lundgren A., Leach S., Tobias J., Carlin N., Gustafsson B., Jertborn M., Bourgeois L., Walker R., Holmgren J., Svennerholm A.M. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine 2013, 31:1163-1170.
103. Tobias J., Lebens M., Bolin I., Wiklund G., Svennerholm A.M. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. Vaccine 2008, 26:743-752.
104. Karlsson S.L., Ax E., Nygren E., Kallgard S., Blomquist M., Ekman A., Benktander J., Holmgren J., Lebens M. Development of Stable Vibrio cholerae O1 Hikojima Type Vaccine Strains Co-Expressing the Inaba and Ogawa Lipopolysaccharide Antigens. PLoS ONE 2014, 9:e108521.
105. Nieves W., Petersen H., Judy B.M., Blumentritt C.A., Russell-Lodrigue K., Roy C.J., Torres A.G., Morici L.A. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin. Vaccine Immunol. 2014, 21:747-754.
106. Petersen H., Nieves W., Russell-Lodrigue K., Roy C.J., Morici L.A. Evaluation of a Outer Membrane Vesicle Vaccine in Nonhuman Primates. Procedia Vaccinol. 2014, 8:38-42.
107. Acevedo R., Fernandez S., Zayas C., Acosta A., Sarmiento M.E., Ferro V.A., Rosenqvist E., Campa C., Cardoso D., Garcia L., Perez J.L. Bacterial outer membrane vesicles and vaccine applications. Front. Immunol. 2014, 5:121.
108. Datta S.K., Sabet M., Nguyen K.P., Valdez P.A., Gonzalez-Navajas J.M., Islam S., Mihajlov I., Fierer J., Insel P.A., Webster N.J., Guiney D.G., Raz E. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10638-10643.
109. Kuate Defo Z., Lee B. New approaches in oral rotavirus vaccines. Crit. Rev. Microbiol. 2014, 1-11.
110. Lua L.H., Connors N.K., Sainsbury F., Chuan Y.P., Wibowo N., Middelberg A.P. Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 2014, 111:425-440.
111. Lencer W.I., Hirst T.R., Holmes R.K. Membrane traffic and the cellular uptake of cholera toxin. Biochim. Biophys. Acta 1999, 1450:177-190.
112. Clemens J., Shin S., Sur D., Nair G.B., Holmgren J. New-generation vaccines against cholera. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:701-710.
113. Freytag L.C., Clements J.D., Eliasson D.G., Lycke N. Use of genetically or chemically detoxified mutants of cholera and Escherichia coli heat-labile enterotoxins as mucosal adjuvants. New generation vaccines 2010, 273-283.
114. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992, 56:622-647.
115. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 1995, 15:317-348.
116. Azizi A., Ghunaim H., Diaz-Mitoma F., Mestecky J. Mucosal HIV vaccines: a holy grail or a dud?. Vaccine 2010, 28:4015-4026.
117. Gloudemans A.K., Plantinga M., Guilliams M., Willart M.A., Ozir-Fazalalikhan A., van der Ham A., Boon L., Harris N.L., Hammad H., Hoogsteden H.C., Yazdanbakhsh M., Hendriks R.W., Lambrecht B.N., Smits H.H. The mucosal adjuvant cholera toxin B instructs non-mucosal dendritic cells to promote IgA production via retinoic acid and TGF-beta. PLoS ONE 2013, 8:e59822.
118. Smits H.H., Gloudemans A.K., van Nimwegen M., Willart M.A., Soullie T., Muskens F., de Jong E.C., Boon L., Pilette C., Johansen F.E., Hoogsteden H.C., Hammad H., Lambrecht B.N. Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. Mucosal Immunol. 2009, 2:331-339.
119. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2001, 20(Suppl. 1):S42-S44.
120. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20:2431-2438.
121. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350:896-903.
122. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., Mills K.H., Rappuoli R., Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19:2534-2541.
123. Brereton C.F., Sutton C.E., Ross P.J., Iwakura Y., Pizza M., Rappuoli R., Lavelle E.C., Mills K.H. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J. Immunol. 2011, 186:5896-5906.
124. Ryan E.J., McNeela E., Murphy G.A., Stewart H., O'Hagan D., Pizza M., Rappuoli R., Mills K.H. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 1999, 67:6270-6280.
125. Jakobsen H., Schulz D., Pizza M., Rappuoli R., Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 1999, 67:5892-5897.
126. Neidleman J.A., Vajdy M., Ugozzoli M., Ott G., O'Hagan D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 2000, 101:154-160.
127. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., Woodrow M., Thierry-Carstensen B., Andersen P., Novicki D., Del Giudice G., Rappuoli R. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009, 4:e6999.
128. Leach S., Clements J.D., Kaim J., Lundgren A. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS ONE 2012, 7:e51718.
129. Sjokvist Ottsjo L., Flach C.F., Clements J., Holmgren J., Raghavan S. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect. Immun. 2013, 81:1532-1540.
130. Lundgren A., Bourgeois L., Carlin N., Clements J., Gustafsson B., Hartford M., Holmgren J., Petzold M., Walker R., Svennerholm A.M. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine 2014, 32:7077-7084.
131. Agren L.C., Ekman L., Lowenadler B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 1997, 158:3936-3946.
132. Lycke N., Bemark M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 2010, 3:556-566.
133. Eriksson A.M., Schon K.M., Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 2004, 173:3310-3319.
134. Sundling C., Schon K., Morner A., Forsell M.N., Wyatt R.T., Thorstensson R., Karlsson Hedestam G.B., Lycke N.Y. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 2008, 89:2954-2964.
135. Abautret-Daly A.E., Davitt C.J., Lavelle E.C. Harnessing the antibacterial and immunological properties of Mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections. Biochem. Pharmacol. 2014, 92:173-183.
136. Cerundolo V., Barral P., Batista F.D. Synthetic iNKT cell-agonists as vaccine adjuvants-finding the balance. Curr. Opin. Immunol. 2010, 22:417-424.
137. Lu W., Chen S., Lai C., Guo W., Fu L., Andrieu J.M. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep. 2012, 2:1736-1746.
138. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
139. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
140. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opin. Drug Deliv. 2011, 8:505-519.
141. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmuller B., Issifou S., Kremsner P.G., Sacarlal J., Aide P., Lanaspa M., Aponte J.J., Nhamuave A., Quelhas D., Bassat Q., Mandjate S., Macete E., Alonso P., Abdulla S., Salim N., Juma O., Shomari M., Shubis K., Machera F., Hamad A.S., Minja R., Mtoro A., Sykes A., Ahmed S., Urassa A.M., Ali A.M., Mwangoka G., Tanner M., Tinto H., D'Alessandro U., Sorgho H., Valea I., Tahita M.C., Kabore W., Ouedraogo S., Sandrine Y., Guiguemde R.T., Ouedraogo J.B., Hamel M.J., Kariuki S., Odero C., Oneko M., Otieno K., Awino N., Omoto J., Williamson J., Muturi-Kioi V., Laserson K.F., Slutsker L., Otieno W., Otieno L., Nekoye O., Gondi S., Otieno A., Ogutu B., Wasuna R., Owira V., Jones D., Onyango A.A., Njuguna P., Chilengi R., Akoo P., Kerubo C., Gitaka J., Maingi C., Lang T., Olotu A., Tsofa B., Bejon P., Peshu N., Marsh K., Owusu-Agyei S., Asante K.P., Osei-Kwakye K., Boahen O., Ayamba S., Kayan K., Owusu-Ofori R., Dosoo D., Asante I., Adjei G., Adjei G., Chandramohan D., Greenwood B., Lusingu J., Gesase S., Malabeja A., Abdul O., Kilavo H., Mahende C., Liheluka E., Lemnge M., Theander T., Drakeley C., Ansong D., Agbenyega T., Adjei S., Boateng H.O., Rettig T., Bawa J., Sylverken J., Sambian D., Agyekum A., Owusu L., Martinson F., Hoffman I., Mvalo T., Kamthunzi P., Nkomo R., Msika A., Jumbe A., Chome N., Nyakuipa D., Chintedza J., Ballou W.R., Bruls M., Cohen J., Guerra Y., Jongert E., Lapierre D., Leach A., Lievens M., Ofori-Anyinam O., Vekemans J., Carter T., Leboulleux D., Loucq C., Radford A., Savarese B., Schellenberg D., Sillman M., Vansadia P., Rts S.C.T.P. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875.
142. Stewart V.A., McGrath S.M., Walsh D.S., Davis S., Hess A.S., Ware L.A., Kester K.E., Cummings J.F., Burge J.R., Voss G., Delchambre M., Garcon N., Tang D.B., Cohen J.D., Heppner D.G. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS, S/AS02A. Vaccine 2006, 24:6483-6492.
143. Silva A.C., Santos D., Ferreira D., Lopes C.M. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes. Curr. Med. Chem. 2012, 19:4495-4510.
144. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., Nakanishi M., Tanaka K., Mayumi T. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J. Control. Release 1999, 61:233-240.
145. Foged C., Arigita C., Sundblad A., Jiskoot W., Storm G., Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004, 22:1903-1913.
146. Wei X., Shao B., He Z., Ye T., Luo M., Sang Y., Liang X., Wang W., Luo S., Yang S., Zhang S., Gong C., Gou M., Deng H., Zhao Y., Yang H., Deng S., Zhao C., Yang L., Qian Z., Li J., Sun X., Han J., Jiang C., Wu M., Zhang Z. Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. Cell Res. 2015, 25:237-253.
147. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., Werninghaus K., Kirschning C., Lang R., Christensen D., Theisen M., Follmann F., Andersen P. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008, 3:e3116.
148. Gram G.J., Karlsson I., Agger E.M., Andersen P., Fomsgaard A. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS ONE 2009, 4:e6950.
149. Kamath A.T., Rochat A.F., Christensen D., Agger E.M., Andersen P., Lambert P.H., Siegrist C.A. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 2009, 4:e5771.
150. Hansen J., Jensen K.T., Follmann F., Agger E.M., Theisen M., Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 2008, 198:758-767.
151. Christensen D., Foged C., Rosenkrands I., Lundberg C.V., Andersen P., Agger E.M., Nielsen H.M. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 2010, 390:19-24.
152. Henderson A., Propst K., Kedl R., Dow S. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine 2011, 29:5304-5312.
153. Nakanishi T., Hayashi A., Kunisawa J., Tsutsumi Y., Tanaka K., Yashiro-Ohtani Y., Nakanishi M., Fujiwara H., Hamaoka T., Mayumi T. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 2000, 30:1740-1747.
154. Tanaka Y., Taneichi M., Kasai M., Kakiuchi T., Uchida T. Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS ONE 2010, 5:e15225.
155. Chen H., Torchilin V., Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 1996, 13:1378-1383.
156. Venkatesan N., Vyas S.P. Polysaccharide coated liposomes for oral immunization-development and characterization. Int. J. Pharm. 2000, 203:169-177.
157. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 2009, 14:541-551.
158. Cox J.C., Sjolander A., Barr I.G. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998, 32:247-271.
159. Sjolander A., Cox J.C., Barr I.G. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol. 1998, 64:713-723.
160. McBurney W.T., Lendemans D.G., Myschik J., Hennessy T., Rades T., Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 2008, 26:4549-4556.
161. Schiott A., Larsson K., Manniche S., Kalliomaki S., Heydenreich A.V., Dalsgaard K., Kirkby N. Posintro-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses. Int. J. Pharm. 2011, 414:312-320.
162. Eliasson D.G., Helgeby A., Schon K., Nygren C., El-Bakkouri K., Fiers W., Saelens X., Lovgren K.B., Nystrom I., Lycke N.Y. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 2011, 29:3951-3961.
163. Aguila A., Donachie A.M., Peyre M., McSharry C.P., Sesardic D., Mowat A.M. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 2006, 24:5201-5210.
164. Andersen C.S., Dietrich J., Agger E.M., Lycke N.Y., Lovgren K., Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 2007, 75:408-416.
165. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9:1149-1176.
166. Kingsman S.M., Kingsman A.J. Polyvalent recombinant antigens: a new vaccine strategy. Vaccine 1988, 6:304-306.
167. Zeltins A. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 2013, 53:92-107.
168. Young K.R., McBurney S.P., Karkhanis L.U., Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 2006, 40:98-117.
169. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., Renner W.A., Muller P., Bachmann M.F. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 2005, 35:2031-2040.
170. Patel K.G., Swartz J.R. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug. Chem. 2011, 22:376-387.
171. Strable E., Finn M.G. Chemical modification of viruses and virus-like particles. Curr. Top. Microbiol. Immunol. 2009, 327:1-21.
172. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., Brown D.R., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Steben M., Bosch F.X., Dillner J., Joura E.A., Kurman R.J., Majewski S., Munoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., James M., Vuocolo S., Hesley T.M., Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 2009, 199:936-944.
173. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., Hurni W.M., Joyce J.G., Lehman E.D., Markus H.Z., Neeper M.P., Schultz L.D., Shaw A.R., Jansen K.U. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. 1997, 176:1141-1145.
174. Jansen K.U., Shaw A.R. Human papillomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med. 2004, 55:319-331.
175. Stanley M., Lowy D.R., Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006, 24(Suppl. 3):106-113. (S3).
176. Felnerova D., Viret J.F., Gluck R., Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 2004, 15:518-529.
177. Gluck R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992, 10:915-919.
178. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344:160-163.
179. Mischler R., Metcalfe I.C. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002, 20(Suppl. 5):B17-B23.
180. Zurbriggen R., Novak-Hofer I., Seelig A., Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 2000, 39:3-18.
181. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., Mouz N., Amacker M., Chalifour A., Diomede L., Devillier G., Cong Z., Wei Q., Gao H., Qin C., Yang G.B., Zurbriggen R., Lopalco L., Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
182. Herbst-Kralovetz M.M. Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines. Ther. Deliv. 2014, 5:741-744.
183. Moser C., Amacker M., Kammer A.R., Rasi S., Westerfeld N., Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 2007, 6:711-721.
184. Hjelm B.E., Kilbourne J., Herbst-Kralovetz M.M. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum. Vaccines Immunother. 2014, 10:410-416.
185. Jackson E.M., Herbst-Kralovetz M.M. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS ONE 2012, 7:e41529.
186. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116:1-27.
187. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012, 64:557-570.
188. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 2013, 3:13.
189. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 2000, 12:456-463.
190. Brayden D.J., Baird A.W. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect. 2001, 3:867-876.
191. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:598-603.
192. Reineke J.J., Cho D.Y., Dingle Y.T., Morello A.P., Jacob J., Thanos C.G., Mathiowitz E. Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:13803-13808.
193. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
194. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28:5-24.
195. Woodrow K.A., Wood M.J., Saucier-Sawyer J.K., Solbrig C., Saltzman W.M. Biodegradable meshes printed with extracellular matrix proteins support micropatterned hepatocyte cultures. Tissue Eng. Part A 2009, 15:1169-1179.
196. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J.X., Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 2000, 50:147-160.
197. Rajapaksa T.E., Bennett K.M., Hamer M., Lytle C., Rodgers V.G., Lo D.D. Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength. J. Biol. Chem. 2010, 285:23739-23746.
198. Marx P.A., Compans R.W., Gettie A., Staas J.K., Gilley R.M., Mulligan M.J., Yamshchikov G.V., Chen D., Eldridge J.H. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993, 260:1323-1327.
199. Pastor M., Esquisabel A., Marquinez I., Talavera A., Pedraz J.L. Cellulose acetate phthalate microparticles containing Vibrio cholerae: steps toward an oral cholera vaccine. J. Drug Target. 2014, 22:478-487.
200. Cahill E.S., O'Hagan D.T., Illum L., Barnard A., Mills K.H., Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995, 13:455-462.
201. Misstear K., McNeela E.A., Murphy A.G., Geoghegan J.A., O'Keeffe K.M., Fox J., Chan K., Heuking S., Collin N., Foster T.J., McLoughlin R.M., Lavelle E.C. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. J. Infect. Dis. 2014, 209:1479-1484.
202. Yan C., Rill W.L., Malli R., Hewetson J., Naseem H., Tammariello R., Kende M. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996, 14:1031-1038.
203. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O'Hagan D.T., Petrilli V., Tschopp J., O'Neill L.A., Lavelle E.C. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:870-875.
204. Netea M.G., Simon A., van de Veerdonk F., Kullberg B.J., Van der Meer J.W., Joosten L.A. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010, 6:e1000661.
205. van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol. 2011, 32:110-116.
206. Katz D.E., DeLorimier A.J., Wolf M.K., Hall E.R., Cassels F.J., van Hamont J.E., Newcomer R.L., Davachi M.A., Taylor D.N., McQueen C.E. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003, 21:341-346.
207. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4:469-478.
208. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.
209. De Smet R., Demoor T., Verschuere S., Dullaers M., Ostroff G.R., Leclercq G., Allais L., Pilette C., Dierendonck M., De Geest B.G., Cuvelier C.A. beta-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. J. Control. Release 2013, 172:671-678.
210. Huang H., Ostroff G.R., Lee C.K., Wang J.P., Specht C.A., Levitz S.M. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect. Immun. 2009, 77:1774-1781.
211. Soto E.R., Ostroff G.R. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug. Chem. 2008, 19:840-848.
212. Brown G.D., Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001, 413:36-37.
213. http://www.accessdata.fda.gov/scripts/fcn/gras_notices/grn000239.PDF.
214. De Jesus M., Ostroff G.R., Levitz S.M., Bartling T.R., Mantis N.J. A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling beta-glucan microparticles. PLoS ONE 2014, 9:e91002.
215. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 1991, 8:713-720.
216. De Campos A.M., Sanchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224:159-168.
217. Miller R.A., Brady J.M., Cutright D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 1977, 11:711-719.
218. Peters W., Brandl J.R., Lindbloom J.D., Martinez C.J., Scallan C.D., Trager G.R., Tingley D.W., Kabongo M.L., Tucker S.N. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013, 31:1752-1758.
219. Aminu M., Ahmad A.A., Umoh J.U., de Beer M.C., Esona M.D., Steele A.D. Adenovirus infection in children with diarrhea disease in Northwestern Nigeria. Ann. Afr. Med. 2007, 6:168-173.
220. Azegami T., Itoh H., Kiyono H., Yuki Y. Novel Transgenic Rice-Based Vaccines. Archivum immunologiae et therapiae experimentalis 2014.
221. Nochi T., Takagi H., Yuki Y., Yang L., Masumura T., Mejima M., Nakanishi U., Matsumura A., Uozumi A., Hiroi T., Morita S., Tanaka K., Takaiwa F., Kiyono H. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10986-10991.
222. Nochi T., Yuki Y., Katakai Y., Shibata H., Tokuhara D., Mejima M., Kurokawa S., Takahashi Y., Nakanishi U., Ono F., Mimuro H., Sasakawa C., Takaiwa F., Terao K., Kiyono H. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J. Immunol. 2009, 183:6538-6544.
223. Tokuhara D., Alvarez B., Mejima M., Hiroiwa T., Takahashi Y., Kurokawa S., Kuroda M., Oyama M., Kozuka-Hata H., Nochi T., Sagara H., Aladin F., Marcotte H., Frenken L.G., Iturriza-Gomara M., Kiyono H., Hammarstrom L., Yuki Y. Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J. Clin. Invest. 2013, 123:3829-3838.
224. Huyghebaert N., Vermeire A., Rottiers P., Remaut E., Remon J.P. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur. J. Pharm. Biopharm. 2005, 61:134-141.
225. Lopez Y., Pastor M., Infante J.F., Diaz D., Oliva R., Fernandez S., Cedre B., Hernandez T., Campos L., Esquisabel A., Pedraz J.L., Perez V., Talavera A. Repeated dose toxicity study of Vibrio cholerae-loaded gastro-resistant microparticles. J. Microencapsul. 2014, 31:86-92.
226. Aramaki Y., Tomizawa H., Hara T., Yachi K., Kikuchi H., Tsuchiya S. Stability of liposomes in vitro and their uptake by rat Peyer's patches following oral administration. Pharm. Res. 1993, 10:1228-1231.
227. Han M., Watarai S., Kobayashi K., Yasuda T. Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization. J. Vet. Med. Sci. 1997, 59:1109-1114.
228. Delgado A., Lavelle E.C., Hartshorne M., Davis S.S. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine 1999, 17:2927-2938.
229. Mowat A.M., Millington O.R., Chirdo F.G. Anatomical and cellular basis of immunity and tolerance in the intestine. J. Pediatr. Gastroenterol. Nutr. 2004, 39(Suppl. 3):S723-S724.
230. Whitacre C.C. New insights into oral tolerance. Gastroenterology 2000, 119:260-263.
231. Clark M.A., Jepson M.A., Simmons N.L., Booth T.A., Hirst B.H. Differential expression of lectin-binding sites defines mouse intestinal M-cells. J. Histochem. Cytochem. 1993, 41:1679-1687.
232. Foster N., Clark M.A., Jepson M.A., Hirst B.H. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998, 16:536-541.
233. Lavelle E.C. Targeted delivery of drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18:341-386.
234. Lambkin I., Pinilla C., Hamashin C., Spindler L., Russell S., Schink A., Moya-Castro R., Allicotti G., Higgins L., Smith M., Dee J., Wilson C., Houghten R., O'Mahony D. Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm. Res. 2003, 20:1258-1266.
235. Manocha M., Pal P.C., Chitralekha K.T., Thomas B.E., Tripathi V., Gupta S.D., Paranjape R., Kulkarni S., Rao D.N. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005, 23:5599-5617.
236. Pickard J.M., Maurice C.F., Kinnebrew M.A., Abt M.C., Schenten D., Golovkina T.V., Bogatyrev S.R., Ismagilov R.F., Pamer E.G., Turnbaugh P.J., Chervonsky A.V. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 2014, 514:638-641.
237. Nochi T., Yuki Y., Matsumura A., Mejima M., Terahara K., Kim D.Y., Fukuyama S., Iwatsuki-Horimoto K., Kawaoka Y., Kohda T., Kozaki S., Igarashi O., Kiyono H. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Exp. Med. 2007, 204:2789-2796.
238. Pappo J., Ermak T.H., Steger H.J. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology 1991, 73:277-280.
239. Zhou F., Kraehenbuhl J.P., Neutra M.R. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 1995, 13:637-644.
240. Hussain N., Florence A.T. Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm. Res. 1998, 15:153-156.
241. Wang X., Hone D.M., Haddad A., Shata M.T., Pascual D.W. M cell DNA vaccination for CTL immunity to HIV. J. Immunol. 2003, 171:4717-4725.
242. Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973, 137:1142-1162.
243. Nussenzweig M.C., Steinman R.M., Gutchinov B., Cohn Z.A. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J. Exp. Med. 1980, 152:1070-1084.
244. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7:790-802.
245. Baumann J., Park C.G., Mantis N.J. Recognition of secretory IgA by DC-SIGN: implications for immune surveillance in the intestine. Immunol. Lett. 2010, 131:59-66.
246. Pantel A., Cheong C., Dandamudi D., Shrestha E., Mehandru S., Brane L., Ruane D., Teixeira A., Bozzacco L., Steinman R.M., Longhi M.P. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur. J. Immunol. 2012, 42:101-109.
247. Iwasaki A. Mucosal dendritic cells. Annu. Rev. Immunol. 2007, 25:381-418.
248. Smart J.D. The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 2005, 57:1556-1568.
249. Nochi T., Yuki Y., Takahashi H., Sawada S., Mejima M., Kohda T., Harada N., Kong I.G., Sato A., Kataoka N., Tokuhara D., Kurokawa S., Takahashi Y., Tsukada H., Kozaki S., Akiyoshi K., Kiyono H. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 2010, 9:572-578.
250. Yuki Y., Nochi T., Kong I.G., Takahashi H., Sawada S., Akiyoshi K., Kiyono H. Nanogel-based antigen-delivery system for nasal vaccines. Biotechnol. Genet. Eng. Rev. 2013, 29:61-72.
251. Fukuyama Y., Yuki Y., Katakai Y., Harada N., Takahashi H., Takeda S., Mejima M., Joo S., Kurokawa S., Sawada S., Shibata H., Park E.J., Fujihashi K., Briles D.E., Yasutomi Y., Tsukada H., Akiyoshi K., Kiyono H. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques. Mucosal Immunol. 2015, [Epub ahead of print]. 10.1038/mi.2015.5.
252. Kazunari A., Kiyono H., Yoshikazu Y., Tomonori N. Mucosal vaccine using cationic +nanogel 2010, (https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010050578&recNum=212&docAn=JP2009068647&queryString=%28%28et/adjuvant%29%20or%20%28ABE/adjuvant%29%29%20AND%20%28%28ET/vaccine%29%20or%20%28ET/immunogenic%29%20or%20%28ET/antigen%29%20OR%20%28ABE/vaccine%29%20or%20%28ABE/immunogenic%29%20or%20%28ABE/antigen%29%29&maxRec=1307).
253. Velasquez L.S., Shira S., Berta A.N., Kilbourne J., Medi B.M., Tizard I., Ni Y., Arntzen C.J., Herbst-Kralovetz M.M. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011, 29:5221-5231.
254. Kunisawa J., Okudaira A., Tsutusmi Y., Takahashi I., Nakanishi T., Kiyono H., Mayumi T. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine 2000, 19:589-594.
255. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 2001, 51:81-96.
256. Thanou M., Verhoef J.C., Junginger H.E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 2001, 50(Suppl. 1):S91-S101.
257. Mori A., Oleszycka E., Sharp F.A., Coleman M., Ozasa Y., Singh M., O'Hagan D.T., Tajber L., Corrigan O.I., McNeela E.A., Lavelle E.C. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur. J. Immunol. 2012, 42:2709-2719.
258. Clemens J., Holmgren J. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?. Curr. Top. Microbiol. Immunol. 2014, 379:231-258.
259. Sur D., Kanungo S., Sah B., Manna B., Ali M., Paisley A.M., Niyogi S.K., Park J.K., Sarkar B., Puri M.K., Kim D.R., Deen J.L., Holmgren J., Carbis R., Rao R., Nguyen T.V., Han S.H., Attridge S., Donner A., Ganguly N.K., Bhattacharya S.K., Nair G.B., Clemens J.D., Lopez A.L. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3years of follow-up of a randomized, controlled trial. PLoS Negl. Trop. Dis. 2011, 5:e1289.